leisure time -WSS

leisure time

author：fashion 2025-09-29 19:04:50 - browse：58

Terry Horgan pictured at home -- coverage from STAT — Terry Horgan in his family's Montour Falls, N.Y., home, in an undated photo. Kate Collins/The Journal via AP

Last October, a 27-year-old man with Duchenne muscular dystrophy died after receiving a CRISPR-based treatment custom built to treat his particular genetic mutation.

Results of a detailed investigation released on Wednesday suggest that the patient, Terry Horgan, likely died of a previously undocumented adverse effect of the virus used to deliver the CRISPR machinery to his cells.

These viruses, known as adeno-associated viruses, or AAVs, are used in several approved drugs and hundreds of clinical trials to deliver genes into patients, because they are generally benign. But at high doses they can cause side effects and, occasionally, deaths through one of several mechanisms, such as directly injuring the liver or triggering a type of immune response known as complement activation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Updated Covid vaccine has 54% effectiveness, new study suggests

hotspot

WSS

Massive project maps cells in human brain in unprecedented detail

A revolution in caring for preterm infants

A single Democrat is willing to weaken Medicare negotiation power

Bernie brings in new pharma CEOs to talk drug prices

A revolution in caring for preterm infants

AstraZeneca stays mum on Medicare drug pricing negotiations

knowledge

leisure time

explore

At least 13 dead in Texas as scorching temps continue

Why Novartis is going to walk from its acquisition of MorphoSys

DIEP, the 'gold standard' of breast reconstruction, is under threat

What's changing in Medicare's open enrollment this year?

New air purifier tech could be key to improving indoor air quality

A revolution in caring for preterm infants

Bright Health sells Medicare Advantage business to Molina

Takeaways from AdvaMed, the largest medical devices conference

What does generative AI mean for health care? We asked experts

What the Wegovy shortage looks like for doctors — and for patients

hotspot

Readout LOUD podcast: Merger Mondays, Ozempic panic

Unique patient identifier: Experts argue the benefits, pitfalls

Massive project maps cells in human brain in unprecedented detail

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Readout LOUD: Venture capital, Gilead, and more M&A

focus

hotspot

knowledge

hotspot